|
|
|
| Effect of curcumin on lung cancer-related LncRNA expression and erlotinib sensitivity |
| XU Yali, CAO Xiaojing, ZHU Xiaozhen, ZHU Guanghui. |
| Department of Pharmacy, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China |
|
| Cite this article: |
|
XU Yali,CAO Xiaojing,ZHU Xiaozhen, et al. Effect of curcumin on lung cancer-related LncRNA expression and erlotinib sensitivity[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2021, 51(3): 225-229.
|
|
|
Abstract Objective: To investigate the effect of curcumin on the expression of lung cancer-related long non-coding RNA (LncRNA) and its sensitivity to erlotinib. Methods: PC9 parent cell lines that belonged to nonsmall cell lung cancer (NSCLC) with EGFR mutation were treated with 20 μmol·L-1 curcumin as the experimental group. Erlotinib-resistant PC9 cell lines treated with 0.9% sodium chloride, Erlotinib-resistant PC9 cell lines treated with 20 μmol·L-1 curcumin and PC9 parent cell lines treated with 0.9% sodium chloride were used respectively as the resistance group, treatment group and control group. The expression of LncRNA MALAT1, LSINCT5, UCA1, HOTAIR, GAS5 and H19 were detected by real-time fluorescence quantitative PCR (qPCR), and the Erlotinib semi-inhibitory concentrations (IC50) of each group cells were detected by CCK-8 assay. Results: Compared with the control group, the expressions of MALAT1, HOTAIR, LSINCT5 and H19 in the experimental group decreased significantly (P<0.05), while there was no significant difference in the expressions of UCA1 and GAS5 and IC50 to Erlotinib (P>0.05). Compared with the control group, the expression of each LncRNA and IC50 to Erlotinib in the resistance group and the treatment group increased significantly (P<0.05). Compared with the
resistance group, the expression of LncRNA MALAT1, LSINCT5, HOTAIR, GAS5 and H19 and IC50 to Erlotinib decreased significantly in the treatment group (P<0.05). Conclusion: Curcumin can regulate the expression of various LncRNA related to EGFR-TKI resistance in lung cancer cells and promote the sensitivity of resistance
cells to erlotinib.
|
|
Received: 29 June 2020
|
| |
|
|
|
| [1] |
. [J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(8): 682-685. |
|
|
|
|
